Sign up
Pharma Capital

VolitionRx reports positive interim results from Danish colorectal cancer study

Cameron Reynolds, chief executive of VolitionRx Ltd (NYSE:VNRX), discusses with Proactive's Andrew Scott the positive interim results from their trial in Denmark concerning colorectal cancer (CRC), which point to being able to detect early signs of the disease.

The ongoing study is in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program.

 

View full VNRX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.